MGI Pharma Inc. said it stopped a Phase III trial of irofulven for gemcitabine-refractory pancreatic cancer, thus ending development of the product in that indication, but also said that pivotal Phase III trials of palonosetron achieved the primary endpoint. (BioWorld Today)

MGI Pharma Inc. said it stopped a Phase III trial of irofulven for gemcitabine-refractory pancreatic cancer, thus ending development of the product in that indication, but also said that pivotal Phase III trials of palonosetron achieved the primary endpoint. (BioWorld Today)

Adolor Corp. and GlaxoSmithKline plc entered a worldwide agreement to commercialize Adolor’s alvimopan in a deal with an up-front payment of $50 million to Adolor followed by the potential of $220 million more in milestones. (BioWorld Today)

Adolor Corp. and GlaxoSmithKline plc entered a worldwide agreement to commercialize Adolor’s alvimopan in a deal with an up-front payment of $50 million to Adolor followed by the potential of $220 million more in milestones. (BioWorld Today)